Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 1279.25 is 103% above its estimated 1-year average of 630.42, near the high end of its estimated 1-year range (568.85–1308.94).
As of 2026-10-06T16:52:29.509Z.
Calculation as of: 2026-10-06T16:52:29.509Z.
Quote observation: 2026-10-06T16:50:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 82cee4a6010f8650e239c44e6fa86f6cad5a1cacb0b867e980d6d40a64789328
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
1279.25
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.10
median of 523 covered companies
CURRENT VS SECTOR MEDIAN
+31101.22%
vs the sector median at left
Market Cap
$245.77M
PS Ratio
153.13
TTM Avg
93.71
3Y Avg
139.93
5Y Avg
235.80
Market Cap
$242.23M
PS Ratio
57.45
TTM Avg
46.85
3Y Avg
41.58
5Y Avg
41.58
Market Cap
$250.93M
PS Ratio
139.79
TTM Avg
23.96
3Y Avg
48.69
5Y Avg
88.66
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $243.06M | 1279.25 | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $244.96M | 4.56 | 2.76 | 7.83 | 16.13 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.32M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $245.77M | 153.13 | 93.71 | 139.93 | 235.80 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | N/A | 1.88 | 1.67 | 1.36 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.23M | 57.45 | 46.85 | 41.58 | 41.58 |
| Galectin Therapeutics Inc. (GALT)vs › | $242.02M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $239.13M | 4.10 | 5.57 | 10.86 | 10.86 |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $250.93M | 139.79 | 23.96 | 48.69 | 88.66 |
| SIGA Technologies, Inc. (SIGA)vs › | $238.48M | 4.44 | 3.23 | 4.18 | 4.64 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-28 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $190,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-28 |
| TTM revenue | $190,000 |
Current P/S: $243,057,476 market capitalization ÷ $190,000 TTM revenue = 1279.25x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T16:50:14.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
At 1279.25, P/S is at an extreme level, where the multiple carries little signal — higher than 98% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
568.85
median
637.24
estimated 1-year high
1308.94
P/S Ratio
1279.25
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 1248.83 |
| 2026-10-02 | 1308.94 |
| 2026-10-01 | 1048.48 |
| 2026-09-30 | 948.31 |
| 2026-09-29 | 914.92 |
| 2026-09-28 | 741.29 |
| 2026-09-25 | 642.91 |
| 2026-09-24 | 661.48 |
| 2026-09-23 | 637.04 |
| 2026-09-22 | 667.42 |
| 2026-09-21 | 637.57 |
| 2026-09-18 | 645.12 |
| 2026-09-17 | 648.93 |
| 2026-09-16 | 649.19 |
| 2026-09-15 | 595.10 |
| 2026-09-14 | 605.25 |
| 2026-09-11 | 681.18 |
| 2026-09-10 | 660.88 |
| 2026-09-09 | 747.96 |
| 2026-09-08 | 619.67 |
| 2026-09-04 | 604.31 |
| 2026-09-03 | 614.06 |
| 2026-09-02 | 642.31 |
| 2026-09-01 | 618.74 |
| 2026-08-31 | 649.39 |
| 2026-08-28 | 591.49 |
| 2026-08-27 | 603.78 |
| 2026-08-26 | 626.02 |
| 2026-08-25 | 588.55 |
| 2026-08-24 | 584.55 |
| 2026-08-21 | 637.44 |
| 2026-08-20 | 602.58 |
| 2026-08-19 | 602.04 |
| 2026-08-18 | 568.85 |
| 2026-08-17 | 588.02 |
| 2026-08-14 | 595.70 |
| 2026-08-13 | 594.36 |
| 2026-08-12 | 600.84 |
| 2026-08-11 | 594.90 |
| 2026-08-10 | 577.67 |
| 2026-08-07 | 601.11 |
| 2026-08-06 | 591.76 |
| 2026-08-05 | 621.08 |
| 2026-08-04 | 658.01 |
| 2026-08-03 | 674.50 |
| 2026-07-31 | 652.46 |
| 2026-07-30 | 687.86 |
| 2026-07-29 | 694.54 |